Cancer Therapeutics Market Trends, Leading Companies, Company Revenue / Sales Performance, Procedure Volume, Healthcare Spending, Technology Adoption, Reimbursement Analysis, Competitive Landscape, and Growth Outlook

Revenue, 2026

USD 232.14 Bn

Forecast Year, 2035

USD 501.07 Bn

CAGR, 2026 - 2035

8.95%

Report Coverage

Global

What is the Cancer Therapeutics Market Size in 2026?

The global cancer therapeutics market size was estimated at USD 212.58 billion in 2025 and is predicted to increase from approximately USD 232.14 billion in 2026, to approximately USD 501.07 billion by 2035, expanding at a CAGR of 8.95% between 2026 and 2035.

Key Takeaways

• North America dominated the market with the largest market share of 36% in 2025.
• Asia Pacific expects a significant CAGR during the forecast period.
• By application, the lung cancer segment dominated the market in 2025.
• By top selling drug, the revlimid segment led the market in 2025.
• By end user, the Cancer and radiation therapy centers segment will gain a significant market share over the forecast period.

Cancer Therapeutics Market Growth Factors

Rise in prevalence of cancer cases and cancer research, surge in collaboration between pharmaceutical companies, and growth in geriatric population are the major factors that augment the growth of the cancer therapeutics market. Furthermore, according to the Globocan 2020 fact sheet, 19,292,789 new cancer cases were diagnosed worldwide, with nearly 9,958,133 deaths owing to cancers all around the world. In addition, according to the International Agency for Research on Cancer (IARC) estimation, by the year 2040, globally the number of cancer patients is expected to grow up to 30.2 million and 16.3 million deaths all around the world. Therefore, rising incidence of cancer cases is expected to propel the need for advanced cancer therapies for the efficient treatment of patients which is likely to boost the cancer therapeutics market during the forecast period.

The pandemic affected health care sector in many extents heading from disturbing regular visits of the patients to the healthcare facilities, leading to the implementation of extra protective measures and social distancing with increased utilization of telehealth and virtual medicine and stressing and overwhelming the health care resources. Moreover, patients with cancer are susceptible population, and they are prone to various harms during pandemics like Covid-19, including but not limited to interruption of their cancer or usual medical care and vulnerability to life-threatening infections. Therefore, oncologists have faced various challenges in order to balance the delivery of high-quality and continuous cancer care with minimizing the risk to the patients during care. In addition, the impact of the Covid19 is likely to be high in developing income countries owing to the availability of poor infrastructure, limited resources, scarcity of medical supplies and personal protective equipment (PPE), shortage of health care providers and organized care teams, and poor access to technology which will result in a shortage of facility to provide and deliver critical care. In addition, in the year 2020, the number of patients diagnosed with cancer around the world reached 19.3 million, and the number of deaths due to cancer raised up to 10 million. Furthermore, there were 2.3 million new cases of breast cancer cases in the year 2020, by representing almost 12% of overall cancer cases. Also breast cancer is also one of the leading cause of cancer death among women.

Market Scope

Segments Insights

Application Insights

The global cancer therapeutics market trends are analyzed across the application vertical in the global report. In addition, the lung cancer is the dominating segment in the cancer therapeutics market, owing to favorable government regulations toward lung cancer therapeutic and rise in prevalence of lung cancer.

Top Selling Drug Insights

The global cancer therapeutics market growth is further analyzed via the top selling drugs vertical in the report. The Revlimid segment comprise of the largest share in the cancer therapeutics market in the year 2025, as it has received a designation of breakthrough therapy. Furthermore, revlimid belongs from immunomodulatory drugs secton. Revlimid is an oral cancer drug utilized for multiple myeloma therapy and treatments. This drug functions against cancer cells partly by affecting the immune system of the patient. In October 2016, the combination therapy results of Revlimid and daratumumab (Johnson and Johnson) reported a rise in progression-free survival rate for patients suffering from relapsed or refractory multiple myeloma. This combination treatment was granted a breakthrough therapy designation by the FDA in the year 2016.

End User Insight

Cancer and radiation therapy centers is the dominating segment of cancer therapeutic market however rising demand for specialty treatment owing to increasing disposable income and health concerns the specialty treatment segment is becoming the fastest growing segment during the forecast period of the market.

Regional Insights

Why Is North America Expected to Lead the Global Cancer Therapeutics Market?

North America is anticipated to conquer the largest share by 2025 owing to heavy funding via numerous organizations and rise in adoption of cancer therapeutics in the region. Moreover, surge in R&D investments is anticipated to facilitate the market growth during the forecast period.

U.S. Cancer Therapeutics Market Size and Growth 2026 to 2035

The U.S. cancer therapeutics market size is expected to reach around USD 133.24 billion by 2035 from at USD 53.57 billion in 2025, representing at a CAGR of 9.54% between 2026 to 2035.

What Factors Are Driving the Growth of the Cancer Immunotherapy Market in Asia Pacific?

The cancer immunotherapy market in the Asia Pacific region, especially in India, China and Japan is expected to witness high growth rate during the forecast period. The growth in this market is expected to be propelled by large population of patient seeking for the cancer treatment, aggressive investment by the major players in the market, increasing prevalence of cancer, increasing government spending on the healthcare, and rising disposable income of the patients has improved the access to cancer treatment in the region. Furthermore, the absence of stringent liberalization and regulations in Asian countries is also a factor turning Asia Pacific a lucrative market for cancer therapeutic.

China Market Trends

China cancer therapeutics market trends consist of a massive drug portfolio and robust research and development space specifically engineered to support modern treatments and medication. The advance next generation patterns, with smart deployment initiatives in clinical trials, are significantly contributing to popular treatments like CAR-T and ADCs. The commercial engagements are a profitable boon to the regional market businesses. Together, the drug portfolio and modern next-generation patterns are promoting precision initiatives to the popular oncology concern. The drug candidates' expansion eventually extends the oncology drug portfolio as well.

Europe's Major Strength in the Market

Europe market is considered to be a significantly growing area, due to its capacity in precision patient care initiatives that continue to polish targeted small molecules and monoclonal antibodies. Whereas modern therapies and regulatory frameworks are setting a benchmark for the regional market evolution. Comprehensive public health management speaks volumes about the oncology treatment and medication effectiveness, followed by the regional medical giants' progressive drug innovation. The biosimilar expansion and the surge of innovative solutions adhering to the regulatory bodies' approval policies are strong backing for the innovative initiatives by the medical enthusiast. The best-in-class health technology assessments is heart of clinical businesses that contribute to the precision treatment oath.

Germany Market Trends

Germany is ahead with its efficient treatments mainly for deadly conditions like cancer. CAR T-cell therapies are a blockbuster in the oncology portfolio. The success of crucial surgeries and radiation therapy expansion is a boon to the regional market. An alternative to painful chemotherapy has been seamlessly overcome with the non-invasive treatment trend supported by suitable equipment and drugs. The accuracy in targeting the cancer cells unlocks the potential of system integration, devices and the expertise of professionals.

Latin America's Development in the Market

Latin America market is expected to grow at a notable CAGR in the foreseeable future. The development in cancer innovation studies marks the best-in-class patient outcomes that highlight the research efficacy. Robust cancer research unveils core oncology trials beneficial for the drug developers' final commercialization. The well-established drug portfolio is a boost to the regional healthcare industries. The growing cases of cancer conditions have enhanced the accessibility of the treatments and drug portfolio as well, with the tech complement in the clinical space. The convincing policies are the backbone of this accessibility thought.

MEA's Innovations in the Market

MEA market is expected to grow at a considerable CAGR in the upcoming period. The innovation is not just limited to the medicine portfolio but also to the commendable tech mechanism deployed in the research settings. The tech companion and system integration are a boon to drug innovations, highly cooperating with the advanced needs in diagnosis and therapeutics. The specialized powerhouses, well known for compatible infrastructure to perform the precision blend, are introducing a range of oncology precision drug portfolios in the final hospital commercialization after a green signal from the medical authorities. The financial backing paves the way for this portfolio admission opportunity.

Cancer Therapeutics Market Companies

• F. Hoffmann-La Roche AG
• Bristol-Myers Squibb Company
• AbbVie, Inc.
• Johnson & Johnson
• Celgene Corporation
• AstellasPharma, Inc.
• Pfizer, Inc.
• Novartis AG
• Merck KGaA
• Eli Lilly and Company

Key Market Developments

• In May 2021, Amgen's LUMAKRAS (sotorasib) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).
• The Cancer Therapeutics Market is highly fragmented with the presence of several local and global companies. These market players are striving to gain higher market share by adopting strategies, such as investments, partnerships, and acquisitions & mergers. Companies are also spending on the development of improved products. Moreover, they are also focusing on maintaining competitive pricing.

Segments Covered in the Report

By Application

• Blood Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Breast Cancer
• Cervical Cancer
• Head and Neck Cancer
• Glioblastoma
• Malignant Meningioma
• Mesothelioma
• Melanoma
• Others

By Top Selling Drugs

• Revlimid
• Avastin
• Herceptin
• Rituxan
• Opdivo
• Gleevec
• Velcade
• Imbruvica
• Ibrance
• Zytiga
• Alimta
• Xtandi
• Tarceva
• Perjeta
• Temodar
• Others

By End User

• Hospitals
• Specialty Clinics
• Cancer and Radiation Therapy Centers

By Region

• North America
• Latin America
• Europe
• Asia-pacific
• Middle and East Africz